Spinal cord and peripheral nerve injury: Current management and investigations

Seminars in Radiation Oncology

Volumn 13, Issue 3, 2003, Pages 322-332

  St Clair, William H ^b   Arnold, Susanne M ^b   Sloan, Andrew E ^b   Regine, William F ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; GLUTATHIONE; HEPARIN; LEVACECARNINE; NAVELBINE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; OXALIPLATIN; PACLITAXEL; SODIUM THIOSULFATE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; WARFARIN;

ATAXIA; AUTONOMIC DYSFUNCTION; BULBAR PARALYSIS; CANCER CHEMOTHERAPY; CANCER SURGERY; COCHLEA INJURY; CONFERENCE PAPER; CONSTIPATION; CRANIAL NERVE INJURY; CRANIAL NEUROPATHY; DEMYELINATING DISEASE; DYSESTHESIA; DYSPHAGIA; DYSPNEA; GUILLAIN BARRE SYNDROME; HEARING LOSS; HUMAN; HYPERBARIC OXYGEN; ILEUS; IMPOTENCE; NEUROTOXICITY; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; OTOTOXICITY; PAIN; PARESTHESIA; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION INJURY; RETINA INJURY; RETROBULBAR OPTIC NEUROPATHY; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SKIN TINGLING; SPINAL CORD DISEASE; SPINAL CORD INJURY; SPINAL CORD TUMOR; SPINE SURGERY; TINNITUS; URINE RETENTION; VERTIGO; VESTIBULAR DISORDER; VISUAL DISORDER;

EID: 0042026869     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(03)00025-0     Document Type: Conference Paper

References (91)

1. De Haas P, Kalkman CJ: Spinal cord monitoring: somatosensory- and motor-evoked potentials. Anaesthesiol Clin North Am 19:923-945, 2001
2. Lipson AC, Gargollo PC, Black PM: Intraoperative magnetic resonance imaging: Considerations for the operating room of the future. J Clin Neurosci 8:305-310, 2001
3. Jacobs WB, Perrin RG: Evaluation and treatment of spinal metastasis: an overview. Neurosurg Focus 11:1-11, 2001
4. Sundaresan N, Krol G, Hughes JEO, et al: Tumors of the spine: Diagnosis and management, in Tindall GT, Cooper PR, Barrow DL (eds): The Practice of Neurosurgery. Baltimore, MD, Williams and Wilkins, 1996
5. Wiggens GC, Mirza S, Ballabarba C, et al: Perioperative complications with costotransversectomy and anterior approaches to thoracic and thoracolumbar tumors. Neurosurg Focus 11:1-9, 2001
6. Siegal T: Current Indications in the management of neoplastic spinal cord compression. Spine 14:223-228, 1989
7. Turnbull IM, Breig A, Hassler O: Blood supply of the cervical spinal code in man. J Neurosurg 24:951-965, 1966
8. Parke, Wesley W: Applied anatomy of the spine, in Horowitz HN, Garfin SR, Balderson RA, et al (eds): The Spine. Philadelphia, PA, Saunders, 1992, 35-88
9. Heller JG: Complications of spinal surgery, in Horowitz HN, Garfin SR, Balderson RA, et al (eds): The Spine. Philadelphia, PA, Saunders, 1992, 1817-1836
10. Hurlbert RJ, Moulton R: Why do you prescribe methyl-prednisolone for acute spinal cord injury?: A Canadian perspective and position statement. Can J Neurol Sci 29:236-239, 2002
11. Wang X, Chun SJ, Treloar H, et al: Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci 22:5505-5515, 2002
12. McDonald JW, Becker D, Sadowsky CL, et al: Late recovery following spinal cord Injury: Case report and review of the literature. J Neurosurg 97:252-265, 2002 (suppl 2)
13. Crameri RM, Weston A, Climstein M, et al: Effects of electrical stimulation induced training on skeletal muscle adaptability in spinal cord injury. Scand J Med Sci Sports 12:316-322, 2002
14. Ishihara H, Kanamori M, Kawaguchi Y, et al: Prediction of Neurologic outcome in patients with spinal cord injury by using hyperbaric oxygen therapy. J Orthop Sci 6:385-389, 2001
15. Blesch A, Lu P, Tuszynski MH: Neurotrophic factors, gene therapy and neural stem cells for spinal cord repair. Brain Res Bull 57:833-838, 2002
16. Lu J, Feron F, Mackay-Sim A, et al: Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord. Brain 125:14-21, 2002
17. Ramon-Cueto A, Santos-Benito FF: Cell therapy to repair injured spinal cords: Olfactory ensheathing glia transplantation. Restor Neurol Neurosci 19:149-156, 2001
18. Woerly S, Doan VD, Evans-Martin F, et al: Spinal cord reconstruction using NeuroGel implants and functional recovery after chronic injury. J Neurosci Res 66:1187-1197, 2001
19. Friedman JA, Windebank AJ, Moor MJ, et al: Biodegradable polymer grafts for surgical repair of the injured spinal cord. Neurosurgery 51:742-751, 2002
20. Stolke D, Sollmann WP, Seifert V: Intra and post-operative complications in lumbar disk surgery. Spine 14:56-59, 1989
21. Horwitz NH, Curtin JA: Prophylactic antibiotics and wound infections following laminectomy for lumbar disk herniation: A retrospective study. J Neurosurg 43:727-731, 1975
22. Disa JJ, Smith AW, Bilsky MH: Management of radiated re-operative wounds of the cervicothoracic spine: The role of the trapezius turnover flap. Ann Plast Surg 47:394-397, 2001
23. Yogev R: Cerebrospinal fluid inspectors: A personal view. Pediatr Infect Dis J 4:113-118, 1995
24. Jones A: Transient radiation myelopathy (with reference to Lhermitte's sign of electrical paraesthesia). Br J Radiol 37:727-744, 1964
25. Thornton AF, Zimberg SH, Greenberg HS, et al: Protracted Lhermitte's sign following head and neck irradiation. Arch Otolaryngol Head Neck Surg 117:1300-1303, 1991
26. Dynes JB, Smedal MI: Radiation myelitis. AJR Am J Roentgenol 83:78-87, 1960
27. Leibel AA, Sheline GE: Tolerance of the brain and spinal cord to conventional irradiation, in Guhn PH, Leibe SA, Sheline GE (eds): Radiation Injury to the Nervous System. New York, NY, Raven Press, 1991
28. Delatta JY, Rosenblum MK, Thaler HT, et al: A model of radiation myelopathy in the rat. Pathology, regional capillary permeability changes and treatment with dexamethasone. Brain 111:1319-1336, 1988
29. Li Y, Jay V, Wang CS: Oligodendrocytes in the adult rate spinal cord undergo radiation-induced apoptosis. Cancer Res 56:5417-5422, 1996
30. Walther PJ, Rossitch E, Bullard DE: The development of Lhermitte's sign during cisplatin chemotherapy. Cancer 60:2170-2172, 1987
31. Van den Bent M, Hilkens P, Smitt P, et al: Lhermitte's sign following chemotherapy with docetaxel. Neurology 50:563-564, 1998
32. Dewar J, Lunt H, Abernathy DA, et al: Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry 49:96-99, 1986
33. Kanchandani R, Howe JG: Lhermitte's sign in multiple sclerosis: A clinical survey and review of the literature. J Neurol Neurosurg Psychiatry 45:308-312, 1982
34. Butler WM, Taylor HG: Lhermitte's sign in cobalamin (vitamin B12) deficiency. JAMA 245:1059-1060, 1981
35. Schultheiss TE, Stephens LC, Peters LJ: Survival in radiation myelopathy. Int J Radiat Oncol Biol Phys 12:1765-1769, 1986
36. Rampling R, Symonds R: Radiation myelopathy. Curr Opin Neurol 11:627-632, 1998
37. Schultheiss TE, Stephens LC, Maor MH: Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys 14:27-32, 1988
38. van der Kogel AJ: Mechanisms of late radiation injury in the spinal cord, in Meyn RE, Withers HR (eds): Radiation Biology in Cancer Research. Philadelphia, PA, Raven Press Inc, 1980, pp 461-470
39. Schultheiss TE: Spinal cord radiation "tolerance": Doctrine versus date. Int J Radiat Oncol Biol Phys 19:219-221, 1990
40. van der Kogel AJ: Dose-volume effects in the spinal cord. Radiother Oncol 29:105-109, 1993
41. Yaes RJ, Kalend A: Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys 14:1248-1259, 1988
42. Hatlevoll R, Host H, Kaalhus O: Myelopathy following radiotherapy of bronchial carcinoma with large single fractions: A retrospective study. Int J Radiat Oncol Biol Phys 9:41-44, 1983
43. Fitzgerald RH, Marks RD, Wallace KM: Chronic radiation myelitis. Radiology 144:609-612, 1982
44. McCunniff AJ, Liang MJ: Radiation tolerance of the cervical spinal cord. Int J Radiat Oncol Biol Phys 16:675-678, 1989
45. Marcus RB, Million RR: The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 19:3-8, 1990
46. van der Kogel AJ: Central nervous system radiation injury in small animal models, in Gutin PH, Leibel SA, Sheline GE (eds): Radiation Injury To The Nervous System. Philadelphia, PA, Raven Press Inc, 1991, pp 91-111, 1991
47. Ang KK, Price RE, Stephens LC, et al: The tolerance of primate spinal cord to re-irradiation. Int J Radiat Oncol Biol Phys 25:459-464, 1993
48. Schultheiss TE, Stevens LC: Radiation myelopathy. AJNR Am J Neuroradiol 13:1056-1058, 1992
49. Hirota S, Soejima T, Higashino T, et al: A case of chronic progressive chronic radiation myelitis treated with long-time corticosteroid administration. Jpn J Clin Radiol 43:649-652, 1998
50. Glantz MJ, Burger PC, Friedman AH, et al: Treatment of radiation induced nervous system injury with heparin and warfarin. Neurology 44:2020-2027, 1994
51. Calabro F, Jinkins JR: MRI of radiation myelitis: A report of a case treated with hyperbaric oxygen. Eur Radiol 101:1079-1084, 2000
52. Marin AC, Rierson B: Peripheral neuropathy secondary to cis-dichlorodiammino-platinum(II) (Platinol): Treatment for advanced ovarian cancer. Ariz Med 36:898-899, 1979
53. Mollman JE: Cisplatin neurotoxicity. N Engl J Med 2:126-127, 1990
54. Greenspan A, Treat J: Peripheral neuropathy and low dose cisplatin. Am J Clin Oncol 11:660-662, 1988
55. Wasserheit C, Frazein A, Oratz R, et al: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity. J Clin Oncol 14:1993-1999, 1996
56. Celik I, Kars A, Ozyar E, et al: Major toxicity of cisplatin, fluorouracil, and leucovorin following chemoradiotherapy in patients with nasopharyngeal carcinoma. J Clin Oncol 14:1043-1044, 1996
57. Grau JJ, Estape J, Cuchi MA, et al: Calcium supplementation and ototoxicity in patients receiving cisplatin. Br J Clin Pharmacol 42:233-235, 1996
58. Kovach JS, Moertel CG, Schutt AJ, et al: Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep 57:357-359, 1973
59. Melamed LB, Selim MA, Schuchman D: Cisplatin ototoxicity in gynecologic cancer patients: A preliminary report. Cancer 55:41-43, 1985
60. Wilding G, Caruso R, Lawrence TS, et al: Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 3:1683-1689, 1985
61. Alderson LM, Noonan PT, Choi IS, et al: Regional subacute cranial neuropathies following internal carotid cisplatin infusion. Neurology 47:1088-1090, 1996
62. Gore ME, Calvert AH, Smith LE: High dose carboplatin in the treatment of lung cancer and mesothelioma: A phase I dose escalation study. Eur J Cancer Clin Oncol 23:1391-1397, 1987
63. Parsons SK, Neualt MW, Lehmann LE, et al: Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669-74, 1998
64. Extra JM, Marty M, Brienza S, et al: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22, 1998 (suppl 5)
65. Culy CR, Clemett D, Wiseman LR: Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895-924, 2000
66. Legha SS: Vincristine neurotoxicity: Pathophysiology and management. Med Toxicol 1:421-427, 1986
67. Graf WD, Chance PF, Lensch MW, et al: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 77:1356-1362, 1996
68. Miller BR: Neurotoxicity and vincristine. JAMA 253:2045, 1985
69. Lonardi F, Pavantato G, Ferrari V, et al: Neurotoxicity after chemotherapy with vinorelbine. Eur J Cancer 29A: 1794, 1993
70. Pace A, Bove L, Nistico C, et al: Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 61:409-411, 1996
71. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990
72. Gordon AN, Stringer CA, Matthews CM, et al: Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: Rapid development of neurotoxicity is dose-limiting. J Clin Oncol 15:1965-1973, 1997
73. New PZ, Jackson CE, Rinaldi D, et al: Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 46:108-111, 1996
74. Faivre S, Kalla S, Cvitkovic E, et al: Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience. Ann Oncol 10:1125-1128, 1999
75. Parimoo D, Jeffers S, Muggia FM: Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst 88:1079-1080, 1996
76. Russell JA, Powles RL: Neuropathy due to cytosine arabinoside. Br Med J 4:652-653, 1974
77. Borgeat A, De Muralt B, Stalder M: Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer 58:852-854, 1986
78. Sarris AH, Hagemeister F, Romaguera J, et al: Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial. Ann Oncol 11:69-72, 2000
79. Koeffler HP, Haskell CM: Rhabdomyolysis as a complication of 5-azacytidine. Cancer Treat Rep 62:573-574, 1978
80. Cavaletti G, Sanna C: Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38:1832-1837, 2002
81. Doolittle ND, Muldoon LL, Brummett RE, et al: Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493-500, 2001
82. Kemp G, Rose P, Lurain S, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
83. Selvaggi G, Belani CP: Carboplatin and paclitaxel in non-small cell lung cancer: The role of amifostine. Semin Oncol 26:51-60, 1999 (suppl 7)
84. Hensley ML, Schuchter LM, Lindley C, et al: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333-3355, 1999
85. Vahdat L, Papadopoulos K, Lange D, et al: Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7:1192-1197, 2001
86. Cascinu S, Catalano V, Cordella L, et al: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478-3483, 2002
87. van der Hoop GR, Vecht CJ, van der Burg MEL, et al: Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 322:89-94, 1990
88. Roberts JA, Jenison EL, Kim K, et al: A randomized, multi-center double-blind placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 67:172-177, 1997
89. Gao W-Q, Dybdal N, Shinsky N, et al: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 38:30-37, 1995
90. Apfel SC, Kessler JA, Adorriato BT, et al: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 51:695-702, 1998
91. Maestri A, De Pasquale Ceratti A, Calandri C, et al: Acetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathy. Proc Am Soc Clin Oncol 21:2476, 2002